Academic literature on the topic 'Psychotropic drugs – pharmacokinetics'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Psychotropic drugs – pharmacokinetics.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Psychotropic drugs – pharmacokinetics"
Fernandes Santos, C., and R. Gomes. "Specificities of the Use of Psychotropic Drugs in Bariatric Surgery." European Psychiatry 65, S1 (June 2022): S478—S479. http://dx.doi.org/10.1192/j.eurpsy.2022.1216.
Full textBOURIN, M., and A. COUETOUX DU TERTRE. "PHARMACOKINETICS OF PSYCHOTROPIC DRUGS IN CHILDREN." Clinical Neuropharmacology 15 (1992): 224A—225A. http://dx.doi.org/10.1097/00002826-199201001-00117.
Full textSit, D. K., J. M. Perel, J. Helsel, and K. L. Wisner. "Pharmacokinetics of psychotropic drugs in pregnancy." Neurotoxicology and Teratology 29, no. 3 (May 2007): 411. http://dx.doi.org/10.1016/j.ntt.2007.03.051.
Full textBurns, Alistair, and Robert Baldwin. "Prescribing psychotropic drugs for the elderly." Advances in Psychiatric Treatment 1, no. 1 (September 1994): 23–31. http://dx.doi.org/10.1192/apt.1.1.23.
Full textMarazziti, Donatella, Stefano Baroni, Michela Picchetti, Armando Piccinni, Marina Carlini, Elena Vatteroni, Valentina Falaschi, Amedeo Lombardi, and Liliana Dell'Osso. "Pharmacokinetics and pharmacodinamics of psychotropic drugs: effect of sex." CNS Spectrums 18, no. 3 (February 4, 2013): 118–27. http://dx.doi.org/10.1017/s1092852912001010.
Full textBaumann, P. "JS01-01 - Pharmacokinetics of psychotropic drugs - keys for treatments’ improvements." European Psychiatry 26, S2 (March 2011): 1995. http://dx.doi.org/10.1016/s0924-9338(11)73698-7.
Full textPichini, Simona, Esther Papaseit, Xavier Joya, Oriol Vall, Magí Farré, Oscar Garcia-Algar, and Rafael de laTorre. "Pharmacokinetics and Therapeutic Drug Monitoring of Psychotropic Drugs in Pediatrics." Therapeutic Drug Monitoring 31, no. 3 (June 2009): 283–318. http://dx.doi.org/10.1097/ftd.0b013e31819f3328.
Full textIannaccone, Teresa, Carmine Sellitto, Valentina Manzo, Francesca Colucci, Valentina Giudice, Berenice Stefanelli, Antonio Iuliano, Giulio Corrivetti, and Amelia Filippelli. "Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters." Pharmaceuticals 14, no. 3 (March 1, 2021): 204. http://dx.doi.org/10.3390/ph14030204.
Full textMoschny, Nicole, Gudrun Hefner, Renate Grohmann, Gabriel Eckermann, Hannah B. Maier, Johanna Seifert, Johannes Heck, et al. "Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs—Influence of Smoking Behavior and Inflammation on Pharmacokinetics." Pharmaceuticals 14, no. 6 (May 27, 2021): 514. http://dx.doi.org/10.3390/ph14060514.
Full textTelles-Correia, Diogo, António Barbosa, Helena Cortez-Pinto, Carlos Campos, Nuno B. F. Rocha, and Sérgio Machado. "Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity." World Journal of Gastrointestinal Pharmacology and Therapeutics 8, no. 1 (2017): 26. http://dx.doi.org/10.4292/wjgpt.v8.i1.26.
Full textDissertations / Theses on the topic "Psychotropic drugs – pharmacokinetics"
Dos, Santos Pereira João Nuno [Verfasser], Jürgen [Akademischer Betreuer] Brockmöller, Gerhard [Akademischer Betreuer] Burckhardt, and Uwe-Karsten [Akademischer Betreuer] Hanisch. "The role of membrane transporters in the pharmacokinetics of psychotropic drugs: in vitro studies with special focus on organic cation transporters / João Nuno Dos Santos Pereira. Gutachter: Gerhard Burckhardt ; Uwe-Karsten Hanisch. Betreuer: Jürgen Brockmöller." Göttingen : Niedersächsische Staats- und Universitätsbibliothek Göttingen, 2015. http://d-nb.info/1068056185/34.
Full textChapy, Hélène. "Identification fonctionnelle et moléculaire d'un transporteur de psychotropes et substances d'abus." Thesis, Sorbonne Paris Cité, 2015. http://www.theses.fr/2015PA05P603.
Full textThe central nervous system is a privilege organ protected by histological barriers between the blood and the nervous tissue. The blood-brain barrier (BBB) and the blood-retinal barrier (BRB) separate cerebral parenchyma and retina from the circulating blood and both express tight junctions and membrane transporters, allowing a precise regulation of the exchanges between the blood and nervous tissues. We studied a new cationic transporter functionally evidenced at the mouse BBB. This molecularly unknown transporter belong to the solute carrier super family (SLC) and is a proton antiporter. It could constitute a new actor in the cerebral permeability and may be a new brain access pathway. First, we worked on the functional identification studying new substrates and new localization. Psychotropic brain transport was studied in vivo by brain in situ perfusion on mouse and in vitro with human immortalized endothelial cells (hCMEC/D3). We showed that cocaine brain entry depends on passive diffusion but also mainly on a proton antiporter. Brain entry rate of drugs of abuse is associated with modulation of addiction liability, making this transporter a new component of brain entry of cocaine, and also nicotine and some amphetamines such as ecstasy and MDPV. This proton antiporter appears to be a new potential target in addiction. Various chemical entities interact with this transporter; however concentrations used to inhibit the transporter are much higher than the one possibly found in the blood. In order to help find or design new selective and potent inhibitors, we developed a pharmacophore model of the proton antiporter inhibitors using in vitro data and the FLAPpharm approach. The model predicts well new possible inhibitors of this transporter. We also studied the impact of the ABC transporters and the proton antiporter at the BBB and the BRB using specific or multi-specific substrates such as verapamil. The proton antiporter is functionally expressed at the BRB and transports clonidine, DPH and verapamil. However, for the multi-specific (P-gp and SLC) compound verapamil, influx transport by the proton antiporter is visible at the BBB only when P-gp efflux is neutralized. On the contrary, at the BRB, the proton antiporter influx is always visible. This is certainly due to the lower impact (by 6.3 fold) of P-gp at the BRB compared to the BBB. These results show the difficulty to predict the functional impact of a transporter for multi-specific compounds and a probable transport prioritization. Finally we worked on the molecular identification of the proton antiporter using a photolabeling method. This work evidenced the importance of the proton antiporter in the brain distribution of psychotropic and drugs of abuse and opened toward new perspectives in addiction and transport comprehension
Santos, Pereira João Nuno dos. "The role of membrane transporters in the pharmacokinetics of psychotropic drugs: in vitro studies with special focus on organic cation transporters." Doctoral thesis, 2015. http://hdl.handle.net/11858/00-1735-0000-0022-5DB2-5.
Full textBooks on the topic "Psychotropic drugs – pharmacokinetics"
N, Musa Mahmoud, ed. Pharmacokinetics and therapeutic monitoring of psychiatric drugs. Springfield, Ill., U.S.A: C.C. Thomas, 1993.
Find full textJ, Ferrando Stephen, Levenson James L, and Owen James A. 1949-, eds. Clinical manual of psychopharmacology in the medically ill. Washington, DC: American Psychiatric Pub., 2010.
Find full textMrazek, David. Psychiatric pharmacogenomics. New York: Oxford University Press, 2010.
Find full textTrachsel, Daniel. Psychedelische Chemie. 2nd ed. Solothurn: Nachtschatten Verlag, 2000.
Find full textRay, Oakley Stern. Drugs, society & human behavior. 4th ed. St. Louis: Times Mirror/Mosby College Pub., 1987.
Find full textCharles, Ksir, ed. Drugs, society & human behavior. 7th ed. St. Louis: Mosby, 1996.
Find full textRay, Oakley Stern. Drugs, society & human behavior. 5th ed. St. Louis: Times Mirror/Mosby College Pub., 1990.
Find full textRay, Oakley Stern. Drugs, society & human behavior. 6th ed. St. Louis: Mosby Year Book, 1993.
Find full textRay, Oakley Stern. Drugs, society, and human behavior. 8th ed. Boston: WCB/McGraw-Hill, 1999.
Find full textRay, Oakley Stern. Drugs, society, and human behavior. 9th ed. Boston: McGraw-Hill, 2002.
Find full textBook chapters on the topic "Psychotropic drugs – pharmacokinetics"
Guimarães, Marília Zaluar Passos, and Gilda Ângela Neves. "Pharmacology of Drugs of Abuse: Pharmacokinetics and Pharmacodynamics of Psychotropic Compounds." In Drugs and Human Behavior, 109–27. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-62855-0_8.
Full textBrøsen, K., and L. F. Gram. "Pharmacokinetic and Clinical Significance of Genetic Variability in Psychotropic Drug Metabolism." In Clinical Pharmacology in Psychiatry, 192–200. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-74430-3_20.
Full textAronson, J. K. "General principles of drug therapy in psychiatry." In New Oxford Textbook of Psychiatry, 1168–77. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199696758.003.0151.
Full textMadhusoodanan, Subramoniam, Marina Tsoy-Podosenin, Leah R. Steinberg, and Nitin Tandan. "Drug interactions involving psychotropic drugs." In Mental Disorders in Primary Care. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198746638.003.0021.
Full textPollock, Bruce G. "Pharmacokinetics and Pharmacodynamics In Late Life." In Late-Life Depression, 185–91. Oxford University PressNew York, NY, 2004. http://dx.doi.org/10.1093/oso/9780195152746.003.0015.
Full textHarrison, Paul, Philip Cowen, Tom Burns, and Mina Fazel. "Drugs and other physical treatments." In Shorter Oxford Textbook of Psychiatry, 709–76. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198747437.003.0025.
Full textVitiello, Benedetto. "Clinical trials methodology and design issues." In Pediatric Psychopharmacology: Principles and Practice, 712–24. Oxford University PressNew York, NY, 2002. http://dx.doi.org/10.1093/oso/9780195141733.003.0053.
Full textGYÜRE, K. I., T. SZENTENDREI, M. I. K. FEKETE, and A. Z. RÓNAI. "THE EFFECT OF NOVEL PSYCHOTROPIC DRUGS ON RAT BRAIN DOPAMINE- AND ALPHA-ADRENERGIC RECEPTOR BINDING IN VITRO." In Receptors and Centrally Acting Drugs Pharmacokinetics and Drug Metabolism, 309–12. Elsevier, 1986. http://dx.doi.org/10.1016/b978-0-08-034191-0.50047-7.
Full textGutierrez, Cynthia A., and Barry S. Fogel. "Pharmacokinetics of Psychotropic Drugs in the Context of General Medical Illness." In Psychiatric Care of the Medical Patient, 448–78. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199731855.003.0022.
Full textLaughren, Thomas P. "Regulatory issues." In Pediatric Psychopharmacology: Principles and Practice, 725–36. Oxford University PressNew York, NY, 2002. http://dx.doi.org/10.1093/oso/9780195141733.003.0054.
Full textConference papers on the topic "Psychotropic drugs – pharmacokinetics"
Schoretsanitis, G. "Establishing therapeutic drug monitoring to routinely assess pharmacokinetic changes for psychotropic medications prescribed during pregnancy and lactation." In XVth Symposium of the Task Force Therapeutic Drug Monitoring of the AGNP. Georg Thieme Verlag, 2024. http://dx.doi.org/10.1055/s-0044-1779547.
Full text